Two members of FDA panel resign in protest over Alzheimer's drug approval

www.nbcnews.com
2 min read
fairly difficult
Two members of a panel of outside advisors to the U.S. Food and Drug Administration have resigned in protest at the agency's decision to approve Biogen Inc's Aduhelm for treatment of Alzheimer's.
Two members of a panel of outside advisors to the U.S. Food and Drug Administration have resigned in protest at the agency's decision to approve Biogen Inc's Aduhelm for treatment of Alzheimer's disease despite the committee's recommendation against doing so.

Mayo Clinic neurologist Dr. David Knopman, a panel member who had been recused from the advisors' November meeting to review the drug because he was an investigator in clinical trials of Biogen's drug, said he…
Reuters
Read full article